Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
Journal of Medicinal Chemistry · 09.11.2023 · 66 (21) · 14897-14911
DOI: 10.1021/acs.jmedchem.3c01398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.10.2023. Verfasst von David Harrison und 10 weiteren Autor:innen. Beteiligte Einrichtung: NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL, Essex, U.K. Hauptthemen laut MEDLINE: Inflammasomes, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: NodThera, Inc..
Abstract (Originalsprache)
The NLRP3 inflammasome is a component of the innate immune system involved in the production of proinflammatory cytokines. Neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, have been shown to have a component driven by NLRP3 inflammasome activation. Diseases such as these with large unmet medical needs have resulted in an interest in inhibiting the NLRP3 inflammasome as a potential pharmacological treatment, but to date, no marketed drugs specifically targeting NLRP3 have been approved. Furthermore, the requirement for CNS-penetrant molecules adds additional complexity to the search for NLRP3 inflammasome inhibitors suitable for clinical investigation of neuroinflammatory disorders. We designed a series of ester-substituted carbamate compounds as selective NLRP3 inflammasome inhibitors, leading to NT-0796, an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 was shown to be a potent and selective NLRP3 inflammasome inhibitor with demonstrated in vivo brain penetration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL, Essex, U.K.
- NodThera Inc., P.O. Box 156, Suite 1702, 265 Franklin Street, Boston, Massachusetts 02110, United States.
- NodThera Inc., 454 N 34th Street, Seattle, Washington 98103, United States.
- Gfree Bio LLC, 5824 Brittlyns Ct, Austin, Texas 78730, United States.
- Rod Porter Consultancy, 89 Back Street, Ashwell, Baldock SG7 5PG, Hertfordshire, U.K.
ORCID-Profile: David Harrison, M Katharine Holloway, Roderick A Porter, Valérie Reader
Förderung
- NodThera, Inc.
Zitieren
APA
Harrison, D., Billinton, A., Bock, M. G., Doedens, J. R., Gabel, C. A., Holloway, M. K., Porter, R. A., Reader, V., Scanlon, J., Schooley, K., & Watt, A. P. (2023). Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders. Journal of Medicinal Chemistry, 66(21), 14897-14911. https://doi.org/10.1021/acs.jmedchem.3c01398
Vancouver
Harrison D, Billinton A, Bock MG, Doedens JR, Gabel CA, Holloway MK, et al. Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders. Journal of Medicinal Chemistry. 2023;66(21):14897-14911. doi:10.1021/acs.jmedchem.3c01398
BibTeX
@article{Harrison2023,
author = {Harrison, David and Billinton, Andy and Bock, Mark G and Doedens, John R and Gabel, Christopher A and Holloway, M Katharine and Porter, Roderick A and Reader, Valérie and Scanlon, Jane and Schooley, Kenneth and Watt, Alan P},
title = {Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {21},
pages = {14897--14911},
doi = {10.1021/acs.jmedchem.3c01398}
}
EUVIMED